A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Ziresovir in Healthy Subjects
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Group, Single Ascending Dose Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Ziresovir in Healthy Subjects
Sponsor: Shanghai Ark Biopharmaceutical Co., Ltd.
Listed as NCT04788017, this PHASE1 trial focuses on Healthy Subjects and remains completed. Sponsored by Shanghai Ark Biopharmaceutical Co., Ltd., it has been updated 6 times since 2021, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Mar 2024 — Jul 2024 [monthly]
Completed PHASE1
-
Mar 2022 — Mar 2024 [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
Sep 2021 — Mar 2022 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
▶ Show 1 earlier version
-
Apr 2021 — Sep 2021 [monthly]
Not Yet Recruiting PHASE1
First recorded
Mar 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Shanghai Ark Biopharmaceutical Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .